Bill C-52 (Historical)

Canada Consumer Product Safety Act

An Act respecting the safety of consumer products

This enactment modernizes the regulatory regime for consumer products in Canada. It creates prohibitions with respect to the manufacturing, importing, selling, advertising, packaging and labelling of consumer products, including those that are a danger to human health or safety. In addition, it establishes certain measures that will make it easier to identify whether a consumer product is a danger to human health or safety and, if so, to more effectively prevent or address the danger. It also creates application and enforcement mechanisms. The enactment makes consequential amendments to certain Acts.

Canada Consumer Product Safety Act

[Glenn Thibeault, NDP, Sudbury, ON]

Mr. Speaker, I am pleased to have the opportunity to speak to Bill C-6 today.

Canadians are in dire need of updated consumer safety legislation. The fact is that more and more consumer products are recalled each year. Many of these products are not made in Canada and, in most cases, those that are imported are imported from China. In fact, products imported from China have often been recalled.

A scan of the latest incidents in today's news reveals toxic drywall from China, high levels of lead found in jewellery imported from China and toaster ovens recalled due to risks of shocks and burns.

Consumers need to know that their government is taking every action to protect its citizens from potentially toxic and harmful products. The sad reality is that consumers are not adequately protected by the outdated Hazardous Products Act. The 40 year old act has not been effective in identifying or removing dangerous products, leaving Canadian dependent on product alerts and recalls by the U.S. product safety commission instead of Health Canada in the majority of cases.

Consumers should receive protection from their own government instead of relying on their neighbours to the south to take action.

Bill C-6 attempts to address some of those weaknesses in the following ways: empowering the government to order the recall of dangerous products; increasing government authority to require information and action from manufacturers and importers; requiring mandatory reporting by manufacturers and importers of incidents involving death or injury from a product's use or any awareness of potential harm from a product or actions taken elsewhere; and, of course, applying heavy fines to violators.

Despite these positive changes, improvements are needed if the bill is to be effective and supportable. Despite the number of changes and improvements to the outdated Hazardous Products Act, our party has some serious concerns with several measures included within the bill. A number of improvements are needed to ensure that the bill is effective and fulfils the spirit of its mandate. I will look at each of them now.

The first concern that New Democrats have with this proposed legislation is the effect or lack thereof on import safety. The fact is that a whopping 65% of consumer goods sold in Canada are imported. The bill, in its current form, lacks any comprehensive system to ensure that items are safe before entering Canada. The risk management approach may target high risk sources for higher surveillance but overall the system depends on reacting to safety problems identified through use after the fact.

A growing problem with the import market is the use of counterfeited approval labels that are also primarily associated with offshore products. This growing concern has not been dealt with.

The United Steelworkers has suggested implementing a stated ban on products containing toxic substances that would be enforced through a pre-entry testing system, financed through a service fee applied at the border. This is one option and another would be to look at the current labelling requirements.

The second concern I would like to address is that there is too much discretion in the hands of the minister. While inspectors have been empowered with greater authority, many of their actions are optional, even when they believe human health is at risk. Related to the issue of discretion is the weak nature of the language contained in the bill. In order to give the bill the teeth it needs to actually protect consumers, the language should and needs to be strengthened. It should be strengthened by changing instances where it stipulates that the minister “may take action” to “has a responsibility to act” or “must act”.

Another particularly alarming omission from this new version of Bill C-6 from its former incarnation of Bill C-52 is the absence of a clause titled “disclosure to public” under the minister's responsibilities. In its current form, Bill C-6 does not require the government to inform consumers of safety issues that have been identified.

Upon questioning of government representatives when this issue came up, it was stated that companies would be less likely to report unbecoming behaviour if they knew it would lead to public scrutiny. What is more important, a business' bottom line or the safety of consumers?

That brings me to another issue with the bill in its current form, labelling.

The review of the 40-year-old act provides a perfect opportunity to beef up the standards for informing consumers and letting them know exactly what ingredients are contained in consumer products. However, if passed in its current form, the bill would allow for the continued sale of products that, by their nature, pose a risk to human safety.

Finally, the bill can look one way on paper but enforcement, as we have seen with the government, seems to be an entirely different story. Though the bill implies a more proactive, aggressive approach to product safety, it is not likely that any of these measures will be put into effect. These measures are completely out of character with the Conservative government's hands-off approach to industry and that what looks good on paper will likely never be put into practice.

In order to make the bill worthwhile there are several amendments that must be made at the committee level.

It is time to show industries that there are two choices: Make safe products and have them allowed in Canada or do not and prohibit them from entering the country. While the bill emphasizes big fines and tougher enforcement, when in history has the government been in favour in interfering in the affairs of business and industry?

Changes need to be made to the legislation to hold the government accountable and responsible for maintaining an adequate inspection capacity and staff to process, investigate and respond to the new reporting system. Without proper enforcement measures holding the government to task to act, there is no guarantee that any action will occur.

The NDP is rightly concerned that the Conservative ideology of non-interfering with business is affecting the safety of Canadian families and their children.

I will now address some of the issues raised by a number of stakeholder groups. The Canadian Cancer Society has a number of recommendations to amend the bill, the first being the removal of the exclusion provision for tobacco products in section 4. This amendment would remove the exclusion provision stating that essentially no part of the consumer product safety act can ever apply to tobacco products.

The second amendment would be adding tobacco products to schedule 1. The effect of this amendment would be that the consumer product safety act would not apply to tobacco products but that there would be flexibility so that in the future there could be a regulation providing that all or part of the act would apply to tobacco products. Tobacco products would thus be treated the same as all of the other products listed in schedule 1, such as explosives, pesticides, drugs, cosmetics and vehicles.

We agree with the Environmental Defence organization as it also has a number of amendments that it would like to see in Bill C-6. The general prohibition in the act should be expanded so that no consumer product can be imported or marketed if it is a danger to human health or safety, either through direct exposure or exposure via the environment. It also calls for a section to be added prohibiting substances on the list of toxic substances from consumer products except where the substance is not a hazard when used in a consumer product or the manufacturer or importer can demonstrate that no reasonable alternative exists. It also asks that a clause be included stating that nothing in the act limits powers to regulate substances in consumer products.

This legislation should include a duty for the government to act when it is made aware of a risk from a consumer product. There should also be a duty for the minister to inform the public when he or she is made aware of a risk in a consumer product.

The bill needs action and, therefore, in deciding whether a danger to health or safety exists, the legislation should require the government to consider the release of harmful substances from products during use or after disposal, including to house dust and indoor air.

The bill should create a hot list similar to that for cosmetics, including carcinogens, reproductive toxins and neurotoxins. These substances should be prohibited in products, with temporary exceptions granted only to the extent that the product is essential and only where alternatives do not exist. At a bare minimum, any product containing such chemicals should be required to carry a hazard label, as is required in parts of the U.S. and the European Union.

The legislation should also establish a list of product classes at highest risk of containing or releasing hazardous substances. There should be explicit guidance prioritizing the routine inspection of these product classes. Furthermore, this bill should require labelling of all ingredients, as is already the case with cosmetics.

Canadian consumers want reliable product safety information and a law that will get unsafe products off the shelves, if not keep them from being for sale in the first place. All parents and, as a father of two young daughters, we want safe products.

New Democrats will do everything to protect all Canadians across our great country.

[Carolyn Bennett, Liberal, St. Paul's, ON]

Mr. Speaker, I am pleased to speak today on Bill C-6, An Act respecting the safety of consumer products.

This enactment modernizes the regulatory regime for consumer products in Canada. It creates prohibitions with respect to the manufacturing, and especially the advertising, selling, importing, packaging and labelling of consumer products that are a danger to human health or safety.

The purpose of this bill is to make it easier to identify a consumer product that may be a danger and to more effectively prevent or address the danger.

The Liberal Party has always had a commitment to improving the health and safety of Canadians. We will continue to support measures which reinforce the regulatory process in order to be sure that Canadians are consuming healthy products.

The purpose of Bill C-6 is to protect the public by addressing or preventing dangers posed to human health or safety by consumer products that are circulated within Canada and those that are imported.

The bill was first introduced as Bill C-52 in the 39th Parliament and was part of the package that also included Bill C-51, which dealt specifically with natural health products. While Bill C-51 was considered contentious legislation, Bill C-52, now Bill C-6, was generally more accepted by stakeholders, but I do not have to tell the government that this is still hugely problematic to many stakeholders.

An analysis of the bill makes evident that the current consumer products safety system functions on a voluntary basis. If a product is dangerous or poses a health threat, the corporations can issue a recall. The new would bill prohibit the sale, import, manufacturing, packaging, labelling and advertising of consumer products that might pose a risk to consumers. While voluntary recalls will continue to happen, inspectors named under the act or by the minister will now be able to order the recall of a consumer product.

The proposed bill will give substantial regulating powers to the minister. It will be necessary to further study these powers to ensure transparency, effectiveness and accountability. It also requires further study to ensure that it can be implemented effectively.

Increased numbers of inspectors will have to be named by the minister and we need to ensure that the human resources and funding are available to do the job properly.

As with Bill C-11, I will be proposing an amendment at the committee stage, instructing the Minister of Health to consult with an expert advisory committee with a mandate to give public advice before the minister can restrict access to a product.

We have been hearing from many stakeholders who are concerned that C-6 will negatively affect access to natural health products.

The Liberal Party has a deep conviction that Canadians have a fundamental right to make their own choices as far as looking after themselves and remaining in good health are concerned, and that we must guarantee them access to those choices. We have no intention of limiting the consumption, sale and distribution of safe natural products. On the contrary, we wish to promote and protect the health and safety of Canadians and improve our regulations so that they may have access to the foods, remedies and consumer products that are the healthiest and most effective.

That is why we asked the minister to submit Bill C-6 to the appropriate committee of the House of Commons before second reading. This would have provided answers to most of the questions raised in your letter. Unfortunately, the minister refused to do so.

I am concerned, yet again, that the proper stakeholder consultations did not take place with regard to Bill C-6 as with Bill C-11. It was clear during the Bill C-11 hearings that the key stakeholders were not consulted properly during the drafting of the bill. As we know information sessions are very different to meaningful consultations.

We have already heard concerns from key stakeholders that Bill C-6 needs an amendment to deal with tobacco manufacturers and another amendment regarding hazardous substances and toxic chemicals, as the member for Etobicoke North so eloquently put forward.

We have been transparent with the Department of Health and provided it with copies of these proposed amendments and will insist that they are included in a future bill.

If this was to be a repeat of Bill C-11, where information sessions were substituted for meaningful consultation, I hope the government has learned its lesson and will make the appropriate government amendments and bring back the witnesses with the most serious concerns and ensure the bill, as amended, would be acceptable to them.

In any bill we need to ensure that Parliament is able to do its job to develop the best pieces of legislation possible, which requires thorough stakeholder dialogue and input.

As I said, the Liberal caucus has asked that the bill be brought to the committee before second reading so it would be possible to make substantial changes as asked for by the stakeholders. We will reluctantly support the bill going to committee after second reading, but we want Canadians to be assured that we will be continuing to be vigilant in the study of Bill C-6 as it enters the health committee, as we had successful changes with Bill C-11.

It is very important that politicians do the politics, that scientists do the science and that the transmission of information from the scientists to the politician is done in a way in which citizens of Canada are included in the decision.

[Colin Carrie, Conservative, Oshawa, ON]

Mr. Speaker, to give the member a bit of my history, I was one of the members who brought forward Bill C-420, which was a natural health products bill. I continue to be involved with that community.

In the original writing of the bill and in the past version, Bill C-52, there was some confusion in the language and stakeholders from the natural health products community required some clarification of it. The minister has written to the chair of the health committee. We will be putting forward an amendment to clarify that exactly so that the stakeholders from the natural health products community know that this bill excludes natural health products and food and drugs under the Food and Drugs Act.

[Colin Carrie, Conservative, Oshawa, ON]

Mr. Speaker, I am pleased to speak in support of Bill C-6. This proposed legislation delivers on the Government of Canada's commitment to improve protection for Canadian consumers through stronger product safety laws. Canadians should be confident in the quality and safety of the products they buy.

The proposed Canada consumer product safety act would modernize our system by raising the bar for industry and by improving protection of the public against the few who would act irresponsibly.

Most Canadian companies manufacture, import and sell safe products and yet, some high-profile safety issues related to consumer products have caused concern among Canadians. These include lead found in imported children's toys and small, powerful magnets found in a variety of children's products that have been known to break off and can then be swallowed by a child. Those incidents highlighted the need to improve consumer product legislation.

This proposed legislation addresses the need to modernize part I of the Hazardous Products Act, an act that has not been amended since its introduction in the late 1960s. Much has changed in the past four decades. Globalization has meant that many consumer goods available in Canada are now manufactured in countries with lower standards for consumer health and safety. Technology has also had an impact. Many of today's consumer goods contain elements and compounds unheard of 40 years ago. So, over time, the safety net that Canadian consumers have come to expect is not as broad as it could or should be.

Allow me to detail a few of the gaps that exist in the current Hazardous Products Act.

It contains no general prohibition against supplying unsafe consumer products that pose an unreasonable danger. It provides only limited authority to detect and identify unsafe products at an early stage. It does not allow government to respond rapidly to unregulated products or hazards. It does not contain the power for government to recall flawed products when a company is unco-operative or slow in doing so.

In short, the existing act needs to be strengthened. Bill C-6, the proposed Canada consumer product safety act, would do just that.

The proposed new act would make it an offence to supply products that pose an unreasonable danger to human health or safety. It would expand the scope of legislation to cover the manufacture of consumer products. It would introduce mandatory reporting of incidents, requiring industry to report when it has knowledge of a serious accident or incident, even if that incident has not caused harm. This would provide an early warning mechanism to allow government to act.

The proposed new act would give the government the authority to require manufacturers and importers to provide results from tests or studies on products. Packaging or labels on products which are false, misleading or deceptive as they relate to health or safety would be prohibited under the proposed legislation. It would require industry to keep detailed records so products could be traced through their supply chain.

The proposed legislation would also introduce an order power so inspectors could require suppliers to recall or take other corrective measures, as well as to take quick action when the supplier failed to do so.

Finally, the proposed act seeks to put in greater deterrents. Fines and penalties would be significantly increased. Maximum fines of up to $5 million would be in place for some offences, while others would have a maximum that would be left to the court's discretion.

We believe these provisions would give Canadian consumers the protection they deserve and expect when they purchase goods ranging from toys to household goods.

There are several groups of consumer products that are regulated by other acts and would not be subject to the proposed legislation. For example, natural health products, which are regulated by a section of the Food and Drugs Act, would not be subject to this proposed legislation. Some stakeholders have expressed confusion about this. As a result, the Minister of Health has written the chair of the health committee to inform her that our government would be moving forward with an amendment to this bill, making it clear that this proposed legislation would not affect natural health products.

Coupled with other initiatives under the food and consumer safety action plan, this proposed act seeks to provide Canadians with a comprehensive scheme for safer consumer products, responsible suppliers across the board and better informed consumers.

This government takes consumer safety seriously and we are taking action. Canadians look to the federal government to show leadership in enhancing the safety of consumer products in this new global marketplace and we are responding.

This proposed new legislation has been developed in consultation with numerous stakeholders and also reflects input made during the discussion on former Bill C-52 in the second session of the 39th Parliament. After 40 years, it brings Canadian consumer protection up to date and provides the same level of protection enjoyed by residents of other countries.

As well, by raising the strength of our product safety system up to the level of our major trading partners, we are safeguarding our marketplace against the risk of becoming a dumping ground for substandard products.

The lowest price can be alluring for consumers and even more so in tough economic times. As a result, we can expect industry to cut corners where it can. Bill C-6 would help prevent any shortcuts on safety. We need the improvements proposed in Bill C-6 now more than ever before.

With the support of members of the House, consumers and businesses will reap the benefits. We have created the ideal package of consumer protection by combining measures to improve prevention, monitor high risk products and act swiftly if a dangerous product enters the supply chain.

Canadians deserve to have confidence when they buy products at their local store. I trust that all members will agree and will join us in supporting Bill C-6.

Human Pathogens and Toxins Act

[Luc Malo, Bloc, Verchères—Les Patriotes, QC]

Mr. Speaker, this morning, my colleagues spoke to Bill C-11, an act to promote safety and security with respect to human pathogens and toxins. Now it is my turn. The summary of the bill reads as follows:

This enactment creates measures to promote safety and security with respect to human pathogens and toxins and all activities associated with them. It establishes a comprehensive legislative regime that extends beyond the present importation regime. It requires every person conducting activities involving human pathogens or toxins to take all reasonable measures to protect the health and safety of the public.

As my colleagues said, it is important to keep Canadians safe. It is every Parliament's duty to ensure the safety of Canadians within the scope of its constitutional powers. As we have seen, the proposed legislation would require all persons conducting these activities to comply with a number of guidelines. It would ensure consistency by obliging all labs to adhere to laboratory biosafety guidelines developed by the Public Health Agency of Canada. Licences must be obtained for controlled activities, such as possessing, handling, using, producing, storing, permitting authorized access to, transferring, importing, exporting, releasing or otherwise abandoning, or disposing of a human pathogen or toxin.

The federal government claims that it is entitled to introduce this bill because of its jurisdiction over criminal law. However, at this point, I have to wonder whether the government should really have made this bill a priority. As we know, since the guidelines were introduced over 15 years ago, there have been no incidents in Canada, regardless of whether labs have been following those guidelines.

Also on the order paper is a bill the government introduced in January, Bill C-6, formerly Bill C-52, on the safety of consumer products. The government has known at least since November 2006 that there are problems in this area. The Auditor General said so. Since the summer of 2007, there have been several major recalls, including a recall of toys containing lead. It would have been better if this bill were before the House now, seeing as how there have been no pathogen problems to date under the existing acts and regulations.

We know that the highest risk groups are groups 3 and 4. I would remind this House that the human pathogens in these groups pose a high risk to the health of individuals and a low or high risk to public health. Twenty-four labs in Quebec and 150 in Canada fully meet the guidelines for groups 3 and 4. In addition, the backgrounder on Bill C-54, which is the number this bill had in the last Parliament, states that “The risk to Canadians posed by the presence of human pathogens and toxins in labs is low.”

This is still a very important issue. However, this bill, in its current form, must not be allowed to stop or impede lab work, which is crucial to determining the causes of diseases and advancing science through research. In committee, it will be very important to look at this aspect of the bill in depth and to meet with a wide range of specialists working in this field to make sure that they will be able to do this work once this bill has been passed, especially with regard to risk group 2, which poses a lower risk to the health of individuals and public health. Of course, these labs include hospital and university labs where very important research is under way.

I would like to raise another point before I go on to the topic of university research. I am just wondering whether the Criminal Code already covers intentional threats to public safety, such as terrorist acts, and unintentional threats, such as criminal negligence. To my way of thinking, these threats to public health or public safety are already covered by legislation passed here.

I would like to start with the issue that, in the current version of the bill could, in our opinion, pose a number of problems. That issue is research conducted in our universities. The parliamentary secretary told us earlier that the government had held a number of consultations. And at a meeting with officials from the Public Health Agency of Canada, we were told that a number of consultations had been held. However, despite these consultations, researchers still have a number of important questions, especially regarding who will pay the costs of complying with the new requirements. This concern is mentioned in the Public Health Agency of Canada notes, but was not addressed by the parliamentary secretary in his earlier remarks.

We know that university research is already underfunded, yet today, as we prepare to refer this bill to committee, we do not know if assistance will be made available to institutions to help them comply with the new guidelines or if labs will be left to cover all the costs themselves.

Has the government actually conducted studies to determine the impact this new legislation would have on university courses, on how our hospitals operate and on the research industry in Quebec and Canada?

This question is extremely relevant because, as I said earlier, I have not yet received an answer. I understand the government's desire to impose a new guideline so that no products are released that could pose a risk to public health, but as for the operations of laboratories, I have yet to receive an answer.

I simply have one question. Does the government want us as parliamentarians to pass legislation that I think is incomplete, in the sense that it does not address all the concerns raised by the community? It is asking us for carte blanche, in a way, and asking us to trust it and wait until later. It seems to be saying that it will communicate with the various stakeholders and labs again, that it will ensure that the regulatory framework will meet their expectations and not pose a problem for their operations. If that is in fact what the government and the department intend to do, why then, from the first draft, from the time this bill was introduced for first reading, has this bill not included provisions to address the concerns justifiably raised by the community?

Once again, the government decided to introduce a bill in this House without assessing the direct impact it will have on the community. If it had done so in a responsible manner, this version of the bill would already include provisions to address the concerns raised by the academic community. We would have already heard the government's response regarding its assessment of the impact of Bill C-11 on university education.

The bill also proposes a number of fines. I understand that when a bill is introduced that will affect the Criminal Code, for example, fines must be imposed. However, what the government wants to do is impose fines on universities and hospitals, when everyone knows very well—and I said so a little earlier in my speech—that there is an abysmal lack of funding for those two kinds of institutions where research is done.

The bill also establishes penalties and fines for anyone who shows wanton or reckless disregard concerning pathogens and toxins. The bill also establishes financial penalties and imprisonment for anyone who intentionally releases pathogens.

I am wondering, as are my Bloc Québécois colleagues, about the need for these new prison sentences given that they are already contained in existing legislation. Are measures put in place by this bill with respect to breach of duty, wanton or reckless breach of duty and intentional release not already in the Criminal Code and the Canadian Environmental Protection Act? And are measures prohibiting intentional misuse of pathogens not included in the Anti-Terrorism Act? These are the questions to ask when the bill is before the Standing Committee on Health.

I am pleased that my colleagues from the Conservative and Liberal parties have agreed to hear important witnesses who, on a daily basis, will have to work under and adapt to this new legislation to establish new standards for storing and handling human pathogens and toxins.

Before concluding my remarks, I would like to go back to two or three other aspects that are more directly related to the bill. Clause 39, for example, states:

The Minister may, without the consent of the person to whom the information relates, disclose personal information and confidential business information obtained under this Act to a person from whom the Minister seeks advice, to a department or agency of the government of Canada or a province, to a foreign government or to an international organization—

For all intents and purposes, although those receiving this confidential information are required to maintain confidentiality—as stated later in the clause—I find it rather strange that consent is not required. It should be understood that the person may not be consulted or, at the very least, notified that information will be disclosed. This could be discussed with the minister and his officials in order to clarify this aspect of the bill, which could be problematic if, in fact, confidential information is disclosed without notifying the individuals or institutions concerned.

I would also like to talk about another issue that relates a bit more directly to the bill. Clause 67 states that the minister may make an interim order involving a product in the case of problems with enforcement of the legislation. The minister would then make an interim order effective immediately. The clause also states that the two houses of Parliament need not be informed for up to 15 days.

Should an emergency occur that requires immediate action on the part of the minister, this House should be informed much sooner than that. Perhaps the parliamentary secretary or even the minister would like to touch on that. When it comes to incidents involving public health and safety, all members of the public, as well as all parliamentarians, should be informed and given the opportunity to debate the issues without delay. To me, that means within hours or, at most, a few days. Fifteen days is far too long. Indeed, it would be odd for Parliament not to be informed of a situation endangering public health within 15 days.

In conclusion, I want to emphasize the importance of ensuring public safety. We must also ensure that our universities and hospitals can carry on doing their research, and that the government provides more support for research.

Resumption of Debate on Address in Reply

[Luc Malo, Bloc, Verchères—Les Patriotes, QC]

Mr. Speaker, I would like to congratulate you warmly on your re-election as Speaker in this House, and would like to inform you that I will share my time with my newly elected colleague from Longueuil—Pierre-Boucher.

First of all, I would like to sincerely and warmly thank all of the voters of the riding of Verchères—Les Patriotes for the great honour they have bestowed upon me by allowing me to represent them once again in this chamber. I would also like to thank all of the volunteers from the bottom of my heart. Some of them worked on my re-election—with Lise Lavoie running the team of volunteers and Robert Laurent acting as official agent—but other volunteers stood up for ideas and proposals for each of the political parties that ran in Verchères—Les Patriotes and throughout Quebec.

And now let us turn to the address in reply to the Speech from the Throne. We had great expectations for this speech. Analysts, citizens, commentators and journalists all said that the Speech from the Throne would focus on the economy. Our retirees are worried when they see their RRSPs shrinking because of the economic crisis and the financial meltdown in full swing on all of the world's stock markets. Our workers are wondering if they will still have work in a few weeks or months and if the work stoppages, which are currently temporary, will continue much longer. We expected the Speech from the Throne to discuss this. But the Governor General was very vague and very unclear when it came to economic issues. The reality is that anything related to social measures, anything that brings to mind the administration that was ousted on the other side of the border on November 4, and anything that reminds us of the presidency that is coming to an end there, that is all still in the Speech from the Throne. The government is still singing the same tune.

The reality is that the Speech from the Throne mirrors the Conservative Party's election platform, a platform which, I should remind the House, was overwhelmingly rejected in Quebec. Ironically, on page 15 of the throne speech, we read, “Parliament is Canada’s most important national institution. It is the only forum in which all Canadians, through their elected representatives, have a voice in the governance of the nation.”

Those words are ironic because the throne speech does not contain any proposals put forward by all the political parties represented here in the House, and it certainly does not represent the values and interests that are important to Quebeckers. The Conservatives decided to pursue the same path they did during the last Parliament, remaining fixated on their dogmatic positions and their own guiding principles. In fact, common sense, the common good and shared values do not really have a place in those principles. Basically, the law of numbers—and remember, the Conservatives have a minority—does not count. We saw this in the last Parliament. The House voted to adopt the Kyoto protocol. The Senate voted to adopt it and royal assent was given to ensure it was respected and enforced in Canada. This government ignored that fact, and I have a feeling that what it says on page 15 of the Speech from the Throne is nothing more than empty rhetoric to impress certain people who are not aware of what happened here.

In contrast—and this has always been our way of thinking, since 1993—the Bloc Québécois evaluates policies issue by issue and suggests practical, effective solutions for the government to implement. We hoped they would listen to us.

The Bloc Québécois is a sovereignist party, a party whose mission is to prove unequivocally to Quebeckers that the only way for Quebec to develop and reach its full potential in a way that honours its values and promotes its national interests is for it to become an independent nation. Nevertheless, the Bloc Québécois respects the institutions and the democratic process established in this House. Out of respect for the majority mandate we received from Quebeckers, we have proposed a sub-amendment to the Speech from the Throne.

Today is Friday, and as the meeting begins, I would like to read it to you. We proposed that the following be added:

that the House recognize that the Speech from the Throne is unanimously decried in Quebec because it reflects a Conservative ideology that was rejected by 78 per cent of the Quebec nation on October 14 and that as a result the House denounce the fact that it does not respond to the consensus in Quebec respecting, for instance, the legislation on young offenders, the repatriation to Quebec of powers over culture and communications, the elimination of the federal spending power and the maintenance of the existing system of securities regulation.

That being said, allow me to now put on my hat as Bloc Québécois health critic to review what the throne speech had to say about health.

Since it was first elected in 2006, this government has been saying that it respects the jurisdiction of Quebec and the provinces. On page 13 of the throne speech, it says that the government will take creative measures to tackle major heart, lung and neurological diseases. That kind of activity falls under the exclusive jurisdiction of Quebec and the provinces. Do I need to point out that Quebec and the provinces are responsible for health care? I will keep pointing it out in committee and in the House as long as I am here. Quebec and the provinces are perfectly capable of setting up programs that support our citizens' health and wellness. The federal government's job is to enable Quebec and the provinces to discharge that responsibility properly through social transfers.

The throne speech also implies that the government will once again introduce the Act to amend the Food and Drugs Act. I would remind the government that there is still a great deal of work to do on this. Many witnesses were ready to appear before the committee when the government decided, of its own volition—because the Prime Minister felt like it—to call an election. Before the election call, individuals and interest groups were ready to testify before the committee. Of course, we still have some reservations, as I mentioned in my speech in June.

Progressive licensing, the government's proposed registration process and the whole issue of inspectors and inspections will have to be reviewed and clarified.

In the bill he introduced in the last parliament, the minister gave himself a great deal of discretionary power. I believe that there will need to be some clarification as to what he intends to do with that discretionary power.

The throne speech also addresses the Consumer Product Safety Act. During the holiday season, consumers buy many products with no way of knowing whether they are safe. Just a few days ago, RCMP teddy bears were recalled because of lead in their belts. As long ago as 2006, the Auditor General said there were problems. The government dragged its feet and did not introduce Bill C-52 until April 2008. We were prepared to examine it in committee. Once again, though, the Prime Minister decided to put an end to all that and call an election, leaving consumers in limbo.

Rather than taking up his responsibilities in this chamber and making progress on the issues, he decided to put his ego first.

I would also like to have spoken about the listeriosis crisis but, given that my time is up, we must simply remember that we need inspectors in every plant and we should not rely on self-regulation. I believe that the government wants to cut inspections and that is not the way to go.

Thank you, Mr. Speaker. I would like to wish you and all my colleagues a good session.

Food and Drugs Act

[André Bellavance, Bloc, Richmond—Arthabaska, QC]

Mr. Speaker, I am pleased to take part in this debate on Bill C-51, An Act to amend the Food and Drugs Act and to make consequential amendments to other Acts.

My hon. colleagues from Laval and Victoria, who spoke earlier, focused on the health aspect and on advertising. Other aspects of this bill also drew my attention. In an effort to keep our viewers at home from losing interest—although the members' presentations were far from boring—I will change the subject somewhat. I will branch off and address the new powers that will be given to the Canadian Food Inspection Agency.

Since I am the agriculture critic for my party, I know it is something that concerns us deeply. People from the Union des producteurs agricoles have also stated their position on the matter.

As we were saying earlier, we in the Bloc Québécois feel it is important that this bill move forward through the legislative process to the committee. This bill raises a number of questions. We have tried to touch on many aspects, but we must ensure that everything is done correctly. That is why we will be very vigilant in committee. I am convinced that my colleague from Laval, as well as my colleague from Québec, who takes care of the health file, will be able to give this bill, if it ever passes, a thorough analysis that will address the concerns of most people.

This bill was introduced at the same time as Bill C-52, which I also spoke to here in this House. We had the opportunity to talk about it earlier this week.

These two bills have to do with health, but they also touch on the agrifood aspect. While Bill C-52 has to do with the safety of consumer products, Bill C-51 could introduce certain measures that I will describe here. During my presentation, I will also explain the traceability system and the recall management system. We are talking about a framework to eliminate damaging effects on health, as well as other areas, but I will focus primarily on those aspects of Bill C-51.

The bill deals with the advertising of drugs, their marketing, approval and traceability. Since we have already had an opportunity to hear about advertising, I will concentrate on traceability, as well as the new powers assigned to the Canadian Food Inspection Agency under the provisions of this bill, which was announced some time ago, at the same time Bill C-52 was announced.

According to a spokesperson for the Canadian Food Inspection Agency, that agency could intervene as soon as a potential health risk became known concerning food imported into Canada. The CFIA could obtain a more precise evaluation of the risk from the country concerned. It could also ask that country for additional evidence of inspection, and standards equivalent to those imposed on our own manufacturers or producers, and of course, not more stringent because of international agreements. We cannot require other countries to impose standards that are more severe than those we apply to our own producers or manufacturers for the very simple reason that we would be contravening the laws and regulations of the World Trade Organization.

However, it is very important that people should know that at present there are still no reciprocal standards. We have said that for a long time and I will have more to say in that regard.

Therefore, unfortunately, under the rules, there are still some products or foods that come into Canada, for example, fruit and vegetables that may come from China—we are always talking about that country—or from India, but also from the United States, on which pesticides, insecticides or certain chemical fertilizers that are forbidden in Canada and in Quebec have been used. In fact, those products are allowed in those countries. It is their choice. I do not necessarily dispute that. They have the right to use the pesticides they want.

Nevertheless, one thing certain is that, here in Canada, there is a very large and well-developed awareness of food safety. We want to use fewer of these products, even though, sometimes, we do not really have a choice. However, we must ensure that where fruit and vegetables are treated in other countries with products that are forbidden in Canada, they cannot cross our border and be sold on the shelves of our grocery stores.

I am very anxious to see that in the application of the law. Undoubtedly, we will look at that issue in committee. Bill C-51 should correct a weakness that we have pointed out many times here in the House, in debate or through questions.

Every time that the Canadian Food Inspection Agency comes to speak to the Standing Committee on Agriculture and Agri-Food, we discuss this. It would be great news if we were able to make these improvements to the inspections.

According to Canadian Food Inspection Agency spokesperson Robert Charlebois—not to be confused with the singer—who was quoted in the April 24 edition of La Terre de chez nous, the Agency will even be able to test products believed to be at risk before they clear customs. That would be a solution to the problem I mentioned earlier. If that were the case, it would be very good.

The Agency currently intervenes when a problem arises, but not before. A number of foods have been recalled from store shelves. When the Agency knows, it does a good job. It issues the recall and the product is removed from the shelves. Nevertheless, there is always room for improvement.

We cannot wait until someone gets sick to take action, although it must be done, since bad things can happen. However, if the Agency had the power, the possibility or the means to intervene before the product even hits the shelves, imagine how many illnesses we could prevent. Cross your fingers. We have not had any deaths, as they have in other countries when a person ingests some of these products, but it happens. We cannot kid ourselves; it happens. There are people in poor health who may ingest foods contaminated with salmonella or what have you, and can die.

It is important to do everything we can to ban these products and ensure that they will not be sold before they hit the shelves, and certainly before they end up on our tables and in our mouths.

The Bloc Québécois is calling on the government to intervene if products enter Quebec and Canada that do not meet our health standards. We have been demanding this for a long time and we will continue to do so.

We also denounced this lack of control over food and other imported goods, and we demanded that the government clean up its legislation in order to eliminate shortcomings that subject the health of Canadians to the goodwill of importers. In this regard, I recently read an article in the April 2 edition of the newspaper Le Soleil. It is very short but nonetheless very revealing. It says:

The Canadian Food Inspection Agency (CFIA) admits that unsafe food from other countries may be made available to consumers, which is a concern for the Minister of Agriculture, Fisheries and Food.

The article is referring to the Quebec minister. It continues:

In the past three years, Canada has had to recall dozens of foods that may have been contaminated.

Michel Labrosse, the Agency's national import operations manager, remarks that people have the impression that the government controls everything, but that is not the case. He noted that unlike meat and eggs, which have a good tracing system, vegetables or processed goods may only have a seal of goodwill from importers and their business partners.

Safety is left primarily up to the importers who, according to Mr. Labrosse, act in good faith 98% of the time.

I do not know whether this is a statistic that Mr. Labrosse truly obtained from the department or if that was his approximation. Nonetheless, if 2% of importers are not doing their job, whether intentionally or not—naturally we hope that it is not intentional but the thought of the money may result in goods not suitable for consumption being put on the market—that is 2% too much.

I will continue with the article from Le Soleil:

Marion Nestlé, a professor at the University of New York, believes that there are holes in the food systems of Canada and the United States that may let in bacteria and other harmful substances. Two years ago, three Americans died and almost 200 others became ill after eating spinach contaminated with E. coli.

I was talking about this earlier. You will remember that American spinach was also removed from our grocery stores.

According to Michel Labrosse, perfectly shaped and blemish free products sought after by consumers have a greater risk of having pesticide or herbicide residues.

I believe that consumers increasingly want good quality products. Regarding appearance, if people notice that a product's appearance is perhaps less shiny because no pesticides or herbicides were used, they may well choose that fruit or vegetable that does not look as great as the bright, shiny ones next to it. They will wonder whether the better looking product was sprayed with all sorts of substances. Consumers are increasingly aware of that kind of thing and they make informed decisions concerning their health and that of their families.

In my speech on Bill C-52 this week, I gave examples of such tainted products: cantaloupe, spinach, which was just mentioned, melamine-tainted pork, pear juice, and carrot juice, all in recent months alone. As we can imagine, there have been many recalls over the past few years. That is why I also called for enhanced inspection powers and, more importantly, the hiring of additional inspectors at the Canadian Food Inspection Agency.

We should make it clear that it is not up to farm producers to pay for the increased inspections and inspection staff. I think that the government's budget can handle the cost of developing an appropriate inspection system. I also pointed out earlier this week that the government had lacked judgment, which prompted a reaction from the Minister of Labour. Perhaps what I meant to say was that the government had been remiss. Considering how long it has been aware of the problem, it should have acted much sooner. I am not going back on what I said, far from it. It is never too late to do the right thing.

All those who were made sick by food they ate that should never have passed inspection here must be telling themselves that they might have been spared the inconvenience had there been more inspections and more inspectors. I think that any parent who has seen his or her child get sick after eating something knows what I am talking about.

So the existing law has to be modernized to reflect new approaches when it comes to safety and traceability. We are told that this is what Bill C-51 does. We intend to send this bill to committee so we can be sure that this will actually be the case. For example, we are told that all importers will have to have a licence. Today, that is only required for importers of meat and fish. The requirement will be expanded to have licences for all food importers, and that is a good thing.

This brings me to the importance of traceability. In Quebec, Agri-Traçabilité Québec was set up in 2001. The mission of Agri-Traçabilité Québec is to contribute to improving food safety and the competitive capacity of Quebec producers. That institution is responsible for developing, implementing and operating a permanent identification system for agricultural product traceability, and covers both animal and plant products. This is what is called the tracking principle, from field to table.

Quebec is well ahead of many countries and also the other provinces, and I am not saying that to pat ourselves on the back. That is what we must be aiming for. It is a good thing that it was developed in Quebec. We are very proud of it, and now it has to serve as an example for the rest of Canada. Whether we like it or not, interprovincial trade means that we are obviously going to be getting food that also comes from the other provinces, and this has to be expanded to other countries as well.

Agricultural producers in Quebec are the first in America to have access to such a highly developed traceability system. It allows for accurate identification of the source of a problem and makes it possible to contain it in order to avoid it becoming endemic or spreading throughout the processing and distribution chain all the way to consumers.

Consumers therefore have greater confidence in our products, in an era when we are affected by irreparable harms, when we think about what happened during the mad cow crisis or the avian flu. We think it does not affect us, but in British Columbia there were poultry destroyed because of a pandemic.

So we are not immune to it. I am also thinking about foot and mouth disease. But I will not list every disease and problem that might arise in cattle, poultry or other livestock. Clearly food safety is a matter of great concern.

Consumers, producers and the entire agri-food industry cannot help but rejoice in the idea that stricter measures and additional resources to enforce them will soon be in place. We will ensure that this happens. And that is what Food & Consumer Products of Canada said in their announcement about Bills C-51 and C-52 in a press release on April 8, from which I will quote a few lines.

The legislation’s focus on risk-based inspection, accountability for importers and strengthening recall provisions for quick intervention when problems arise, would significantly improve Canada’s ability to detect contaminated food and consumer products...Focusing on imported goods from countries or companies with a history of problems just makes sense. Increasing our ability to scrutinize and oversee imports based on risk greatly enhances our ability to detect threats to public health without crippling commerce or violating our trade commitments.

That shows that there are positives to consider in this bill. That is what my colleague from Québec, health critic for the Bloc Québécois, and I conveyed in this House on April 1 when we questioned the government about food inspections. The Canadian Food Inspection Agency's failure to monitor imported products is resulting in a lower level of compliance for foodstuffs, thereby threatening food safety for consumers. We demanded food security measures, and we have no intention of letting up simply because this bill has been introduced.

We have already mentioned that the Quebec government and a number of experts have denounced the failure to monitor imported food. This situation not only threatens consumers, but also producers because the imported products do not meet the same standards as local products, as Christian Lacasse, president of UPA, said.

I think that I have gone into enough detail about this issue over the past few minutes for the people to understand how important it is to us that there be reciprocity with respect to standards for pesticides, insecticides and herbicides in the countries with which we trade. It is unacceptable that chemical products banned here, such as pesticides, insecticides, herbicides and some fertilizers, can be used on foods produced in other countries that end up on our grocery store shelves.

I look forward to seeing if Bill C-51 will bring about any real changes to this state of affairs. It is time for the government to demand trade reciprocity. That is why the committee will be especially vigilant in its work to ensure that the necessary resources to enforce the new rules are clearly provided for in the bill.

I see the time, and I get the feeling that I do not have much left, but I want to say that some of the objectives in this bill need to be emphasized, such as avoiding problems by instituting broader targets for potentially unsafe food imports, increasing the government's power to prevent problems by requiring the industry to implement monitoring for unsafe foods, and expressly forbidding the modification of foods. We also want to improve targeted monitoring by increasing the government's power to verify food safety at all points along the supply chain, including before they are imported into Canada.

I have often said that it is important to go to the source to see exactly how foods are grown. We need to know that. We need to do that. If foods are not produced in accordance with our environmental standards, even if it is just a problem with the water used to grow the food, we should simply tell those countries that their products cannot come here.

In conclusion, we also want to support rapid intervention by creating a new power that requires those modifying foods to keep files, by improving access to the information needed to follow up efficiently on problems that arise, and by modernizing and simplifying inspection systems. If we achieve that, it will be a step in the right direction.

[Denise Savoie, NDP, Victoria, BC]

Mr. Speaker, it is my pleasure to speak to Bill C-51, which is being presented in tandem with Bill C-52, which I spoke to earlier.

Bill C-51 seeks to amend the Food and Drugs Act. It has some positive aspects. A bill to better protect consumers is long overdue. Canadians have suffered harm from recalled products and death from drugs that were approved for sale too quickly.

The Food and Drugs Act has been eroded over long years of the former government. Canadians, it seems to me, have lost confidence in the government's ability to protect their health. Perhaps it has to do with the former government's big love affair with large pharmaceutical firms, but whatever the cause, Canadians feel that their health is not being protected, and this is what we must address.

In its present form, the bill is hugely inadequate and there is much that is worrisome about it. I have received literally hundreds of emails and letters about the bill. I would like to read some of them because they provide some interesting insights on how Canadians feel right now.

The official intent of Bill C-51 is to fill in gaps in health protection and to ensure the safety of Canadians. To that end, the bill proposes to implement sweeping changes in how Health Canada will regulate drug products.

As I have said, there are fundamental aspects that are problematic and that will keep the bill from doing what it purports to do, which is protecting Canadians. Instead, some of what is in the bill could likely have an adverse effect on Canadians' health.

I would like to touch on a few subjects that the bill addresses. The first one relates to advertising. In the modification that the bill proposes, it would likely have the effect of providing an opportunity for drug manufacturers to bypass the advertising bans by applying for exemptions. This simple change is disturbing in that it would render the government vulnerable to lobby pressure by large pharmaceutical multinationals.

It is important for Canadians to have clear information about the health product they take. We should not reasonably expect companies to advertise their products and expect that they will do so to educate Canadians.

I want to refer to some testimony that was given at committee by an independent drug policy researcher from my city of Victoria. I stress “independent” because often when presentations are made at committee they are made by people who either have ties to pharmaceutical companies or push for policies that improve the profits of the companies. It is important to mention that this researcher, whose name is Alan Cassels, is an independent researcher. He made the following comments at committee recently:

The pharmaceutical industry spokespeople will tell you that they should be involved in the education of consumers about drugs, but let me show you how they choose to educate consumers. This “toe tag” ad appeared in many magazines and major newspapers across Canada. This one came from the National Post of February 20, 2004. It shows a toe tag hanging off a corpse with the headline, “What would you rather have, a cholesterol test or a final exam?” Here's another example, from Maclean's magazine, of the same ad.

These ads are probably the most egregious example of disease-mongering that this country has ever seen. The ads, which ran in both France and Canada, were the subject of a letter from the World Health Organization to the medical journal The Lancet, complaining that this kind of advertising is undoubtedly driving the inappropriate use of cholesterol-lowering drugs around the world.

This proposed policy would be a policy basically on disease-mongering. It is important to maintain our current ban on direct to consumer advertising of pharmaceuticals but we need to go further than that. We actually need more strict control on the advertising of diseases. The industry might call it disease awareness but it may be closer to the truth to call it disease-mongering.

One place to start would be to ask Health Canada some hard questions. What is our policy around this so-called industry advertising? Do we collect data if this kind of advertising is driving the inappropriate use of pharmaceuticals? What research into this kind of approach has been commissioned? What other steps is Health Canada taking to control it? Instead of trying to deal with patients who may be dying from prescription drugs, how can we stop people from taking drugs they do not need in the first place?

The last question, a question that Mr. Cassels raised in committee, is very important. This is an aspect of proactive health, which we just do not do in Canada, that is inadequately funded and has not received enough resources, energy and thought.

We should not be allowing any shortcuts to advertising. Instead, we should be providing better information for patients. There is a dire need for Canadians to receive approved and regulated information provided by an independent, objective source that is free from profit driven industries that sell drugs. This bill would not do that.

At committee, the NDP will be seeking to ensure that there is no direct to consumer advertising and that it will be completely removed from the bill. We cannot allow that to happen.

Another aspect of the bill that is of concern is that it takes a radically different expedited approach to the drug approval process, which the government calls progressive licensing. Progressive licensing would have the effect of speeding up the process of new drugs to the Canadian marketplace. It sets up an ongoing life cycle approach without any new improvement to the pre-market testing of new drugs.

This is the first time a bill of this sort codifies the trade agreements, like NAFTA, for grounds for refusing to release information about safety and efficacy that companies submit in order to get their products approved. This clause is absolutely objectionable and needs to be removed and replaced by making transparency the default option.

If we want Canadians to take responsibility for their health, they must be able to make better informed decisions and that comes about with more awareness about what particular drugs do and having some choices in the drugs they are allowed to take.

One needs to ask whether this new provision would prevent similar recalls as occurred under Vioxx. Will it prevent another Vioxx type of recall? It appears highly unlikely. Therefore, my colleagues and I will be looking for dramatic changes on this aspect at committee as well.

Bill C-51 also raises the question about the speed with which drugs will be moved through the approval process. This really relates to parliamentary oversight and the kind of parliamentary oversight we should be requiring. The provisions in the bill would make it possible to grant conditional approvals, thereby getting new drugs to market faster than is possible under the current regulations. Pre-market safety requirements may be less stringent or even be bypassed all together according to the stipulations of the bill.

There also is no commitment in the bill to making the results of post-marketing studies public, which is another concern.

Another troubling aspect of the bill is that it would provide the Minister of Health and Health Canada with considerable discretionary authority that falls outside the purview of Parliament. In other words, Bill C-51 could effectively remove democratic oversight, bypassing elected officials in favour of allowing bureaucrats to enforce regulations that fall short of the standards Canadians deserve.

I spoke a little about the kind of information that is really important for Canadians to access in order to make crucial health decisions on the safety of the products they are taking. Perhaps the most onerous change that is being proposed in the bill relating to the Food and Drugs Act involves the provisions regarding natural health products. Many Canadians prefer to look for complementary strategies to stay healthy. I myself benefit from such products and it does help me to stay much healthier.

The provisions in the bill are worrisome because among the modifications proposed by the bill are radical changes to key terminology, for example, replacing the word “drug” with “therapeutic products” throughout the bill and therefore bringing the natural health industry under the scope of the Food and Drugs Act and Health Canada. This far-reaching change would give the Minister of Health broad powers to regulate all natural health and plant derived products and, in the process, restrict access to these products for Canadians.

Up to 60% of the natural health products currently on the market would be outlawed as a direct result of the enactment of Bill C-51. This would remove a lot of choices for Canadians.

From some of the many letters I have received, there is one from a medical doctor who says, “I'm a medical doctor and a doctor of Chinese medicine living and working in Victoria. I'm becoming concerned that the new Bill C-51 introduced by the health minister might affect the public's and my patients' access to natural health products in Canada”.

Indeed, the clauses in this bill would have a serious limiting effect.

It is not by succumbing to the big pharma lobby that we will achieve balance in better regulating natural health products. That is an important piece: we must have a better balance. Perhaps we can do it by creating a third category. This something that the natural health industry has been calling for. Instead of buckling under to the big pharmaceutical lobby, it would simply have its own category, by itself, and regulations that do achieve that balance.

Another comment I have received which has concerned me is the following: “I and my family are opposed to Bill C-51 as it will restrict access and increase prices of natural health products we use regularly”. I think we are all aware that right now Canadians are having a more difficult time. Our economy is in decline. Many people are struggling to make ends meet and are using natural health products to stay healthy. Increasing the prices at this time would certainly not be helpful.

Another comment from one of my constituents states: “Regulations of natural health products should be separate from pharmaceuticals”. This is something that I think we will be asking the committee to look at.

Another comment that has been made is in regard to concern about how quickly this bill is being pushed through the process, disregarding recommendations made by many consumer public forums, health coalitions, and so on.

For the many people who suffer from chronic illnesses of various kinds, I think access to natural health products really keeps them functioning and protects their quality of life. This is what they are asking us to do. I will be asking members of the committee to look at this aspect of the bill very seriously to see if the draconian measures being proposed really warrant what is being asked. Merely selling garlic to someone would make it a drug product under this new definition. Does that make any sense? There are many other examples like that.

I see that I am running out of time, so I will conclude simply by saying that Canadians want to be able to use natural products to keep their families in good health as one of the many ways used to maintain health. Being forced to use a pharmaceutical option is not the way to go. That is something I am going to oppose.

I hope the committee will look at making these much needed amendments while protecting the overall purpose of the bill, which is to ensure that products sold to Canadians are safe.

[Nicole Demers, Bloc, Laval, QC]

Mr. Speaker, I thank my colleague for her question.

In fact, that is a subject I did not address: the subject of confidentiality and everything relating to drugs that are approved, not approved and awaiting approval. There again, there are major roadblocks for ordinary consumers and people who want to know what they are consuming, who want to know how and why they consume it, and most importantly, if it is a drug, a therapeutic device or a surgical device, whether it is harmless or not.

Some day, and I hope that day comes soon, we are going to have to adopt some clear rules. There is a lot of talk about transparency, but we are going to have to get beyond talking and have some actual transparency.

We have been talking about transparency since I first came to this House, but everything is just as opaque everywhere, in all fields, as if no one had ever talked about transparency. People have to know, they have to be aware, they have to be sufficiently educated and informed about all the drugs and products they may take so they can make informed choices.

It is exactly the same thing with GMOs and therapeutic products. I referred earlier to essential oils in relation to Bill C-52. It is the same thing. Consumers have a right to know. Consumers seem to be very wise, because it is letters from consumers that are telling us to be careful and not let a minister do the work by himself and make decisions about a bill by himself.

This may not relate directly to the bill itself, but rather to the direction taken in the bill. If the minister can change the direction taken by a bill once it has been agreed to and passed, what point is there in sitting in this House, doing the essential work and drafting a bill like this to ensure that our fellow citizens, and consumers, have access to quality drugs and that their health is not in danger?

What point is there in doing all these studies and all this research, in bringing thousands of witnesses here, if the Minister of Health can ultimately get up one fine morning and say he no longer agrees with the direction taken in the bill and decide to change it? I think my colleague is right to be worried.

Business of the House

[Peter Van Loan, Conservative, Leader of the Government in the House of Commons and Minister for Democratic Reform]

Mr. Speaker, our week devoted to action on the environment and health of Canadians is proving to be a success. We just passed Bill C-33 at report stage with the support of two of the other three parties. This is our bill requiring that by 2010 5% of gasoline and by 2012 2% of diesel fuel and home heating oil be comprised of renewable fuels. It represents an important part of our plan to reduce greenhouse gas emissions by 20% by 2020. Debate of this bill at third reading will now be able to commence tomorrow.

We have also started to debate two bills to improve the safety of food, consumer products and medical products in Canada.

On Monday we debated Bill C-52, to create the Canada Consumer Product Safety Act and yesterday we debated Bill C-51, to modernize the Food and Drugs Act.

We also introduced Bill C-54, to promote safety and security with respect to human pathogens and toxins. We will continue to debate these bills today and tomorrow.

During these uncertain economic times to the south, our government has led the way on the economy by taking decisive and early action over the past six months to pay down debt, reduce taxes to stimulate the economy and create jobs, and provide targeted support to key industries. In keeping with our strong leadership on the economy, next week will be maintaining a competitive economy week.

We plan to debate the following bills intended to enhance the competitiveness of certain sectors of the Canadian economy: our Bill C-23, at third reading stage, to amend the Canada Marine Act; our Bill C-5, at report stage, on liability in case of a nuclear incident; and our Bill C-14, at second reading stage, to amend the Canada Post Corporation Act.

We will also debate at second reading Bill C-32, which modernizes the Fisheries Act, Bill C-43, which amends the Customs Act, and Bill C-39, which amends the Canada Grain Act. We will also begin to debate Bill C-46. This is our bill to free western barley producers from the Canadian Wheat Board monopoly by giving them the freedom to market their own products. We will debate at third reading our bill to amend the Aeronautics Act, Bill C-7.

My friend, the member for Wascana, the Liberal House leader, said that government business and the doing of business in the House of Commons appeared to end on Tuesday. That is because next Wednesday and Thursday will be opposition days, and I would like to allot them as such at this time.

In terms of the question he raised with regard to Bill C-293, which is a private member's bill, I understand it is scheduled to come before the House in early May. At that time the House will have an opportunity to deal with the matter.

In terms of estimates and witnesses appearing before committee of the whole, the government does have to designate those to occur before May 31. Late last night I finally received notice of which two departments were identified and we will soon be advising the House of the dates that will be scheduled for consideration of those matters in committee of the whole.

Food and Drugs Act

[Steven Fletcher, Conservative, Parliamentary Secretary for Health]

Mr. Speaker, I assure the member that there are no shortcuts when it comes to clinical trials. In fact, the bill, through the life cycle approach, is much more effective in ensuring the safety of Canadians because it would allow the government to monitor the products after they reach the market.

I will also address a concern raised by the Bloc. Proactive measures have been taken by the minister and the government. It has been demonstrated with the presentation of Bills C-51 and C-52. It has been demonstrated again in budget 2008 in which $113 million has been invested to ensure that we will have a food and consumer safety action plan that is well funded.

Will the member agree that a life cycle approach is the right way to go and that it is important for the Minister of Health to have the ability, in rare but extreme cases, to remove a product off the shelf? Those are really the main points of the bill. I hope the member will be open to accepting that the government is on the right track without predetermining, what is so often the case, negativity.

Does the member agree with the life cycle approach and mandatory recall, if necessary?

[Christiane Gagnon, Bloc, Québec, QC]

Mr. Speaker, I am pleased to speak to second reading stage of Bill C-51 to amend the Food and Drugs Act. We know this act has been around for 40 years and that not too many changes have been made to it with respect to food and drug safety.

Bill C-51 bears a strong resemblance and is closely related to Bill C-52, which seeks to better monitor products on the market and reassure the public about product safety.

Here the government is taking things a bit further. It wants to cover other products, including pharmacological products, and look at pharmacovigilance.

Why does the government want to modernize this act? Because the public is quite worried. In the past few months and years, it has come to our attention that some products are harmful to our health. Certain drugs have adverse effects causing death.

For example, there is Singulair produced by Merck Frosst. This is an asthma drug that causes suicidal ideation. Champix, an anti-smoking drug produced by Pfizer, also causes suicidal ideation and depression. What is more, anti-psychotic drugs for children apparently cause obesity. These are some of the harmful effects of taking those drugs.

More and more people are worried about some of the drugs on the market. Some consumer products, such as children's toys or toothpaste from South Africa, also contain toxic substances. Other products contain mercury. The government is introducing this bill, which it was asked to do, to reassure the public about drug safety.

The minister has been asked about this a number of times. In 2006, the Auditor General issued a scathing report saying the government should make some changes. The lack of control by the Canadian Food Inspection Agency was among the Auditor General's many criticisms. Even that agency admits that unsafe products may be found on the shelves and that the public has cause for concern.

Will the bill properly respond to this situation and ensure food and drug safety?

The minister probably wants to reassure citizens with his bill. The purpose of Bill C-52 is to increase the industry's accountability with regard to the food supply. The government may also require that food safety monitoring be implemented. To that end, it gives the minister the authority to conduct inspections at any time. It will also require the industry to report the adverse effects of consuming certain foods. It also provides for a tracing system not just for foods but also for cosmetics and therapeutic products.

Is this the right approach? The objectives are laudable. How will it be done? We know that a whole set of regulations will come after the bill. However, today, we cannot discuss the regulations because they are not available. We hope that they will be provided when the bill is studied in committee. With regard to the Assisted Human Reproduction Act, passed in 2004, only one regulation was submitted to committee review and we are still waiting for the regulations. We hope that the regulations will follow on the heels of the bill so that they may be debated in committee.

Will the government meet the expectations of Canadians?

In response to the fears surrounding the safety of food and therapeutic products, the Auditor General was headed in the right direction when she sounded the alarm for the government by asking it to increase human resources and particularly to provide funding for inspections.

We need only think of natural products, for example. We know that there are between 33,000 and 40,000 products waiting for inspection in order to be licensed because of the shortage of inspectors. This applies not just to natural products but in particular to foods and consumer products. The inspectors quite often do not have the requisite training to properly inspect all these products.

There was a call for better training for staff and better human resources. I am afraid that this objective is not met by this bill. We can see that resources are lacking, as I was saying. Concerns about these shortcomings were expressed not only by the Auditor General but also by the Canadian Food Inspection Agency.

Today, Bill C-51 goes one step further. In committee, we are studying aspects of post-market monitoring and pharmacovigilance. Over the past few months, we have met with experts and witnesses. We would have hoped to see Bill C-51 drafted along the lines that the committee suggested to the minister after it received recommendations from experts. However, he got a little ahead of the committee's work, and there was some duplication.

We are now considering this bill at second reading. We will vote in favour of the bill because we want it to be referred to committee for further study. That means that we will have to invite the same number of people, the same experts, to come tell us what they think about this bill. We would have hoped that the minister would have waited for our amendments and recommendations.

That is not what happened, so we hope that the minister will be open to some amendments to the bill in areas where he did not take into account all the concerns of the witnesses who appeared before the committee. We hope that the government will be open to these amendments. I am sure that amendments will be proposed, because the bill does not adequately address the issue of food and therapeutic product safety.

I would also like to talk about adverse drug reactions, which the bill addresses. Various experts commented on this and clarified things for us. That is what we would have liked to pass on to the minister before this bill was introduced. For example, consider hospitals' obligation to report on adverse drug effects, as set out in the bill. Many witnesses told us that that might not be the best way to go. Currently, between 1% and 10% of adverse effects are reported. Is the government hoping that by introducing this measure, that incidence will go up? Probably.

We would like to see greater interest in the reporting of adverse effects, but not just any old way. Some witnesses told us that hospitals may not have appropriate structures in place to fulfill this obligation. It might be too much red tape.

I do not know what kind of clarification the minister will provide on this issue. Regardless, we would have hoped to have had an opportunity to submit our recommendations after analyzing all of the testimony.

As I was saying, the bill also seeks to create a register of adverse reations.

We wonder about the reporting of serious and rare adverse reactions, but especially about how this information will be passed on so that health professionals are kept abreast of information from the adverse reaction register. The frequency of common adverse reactions is already known because of clinical trials. According to some witnesses, what is important is what we do not know, the unknown reactions.

With regard to mandatory reporting by hospitals, as I said, since all adverse reactions will have to be reported, not just unknown and more serious reactions, hospital pharmacists are afraid their workload will increase significantly. Should the emphasis be on the quantity or the quality of adverse reaction reports? An increase in the number of reports could dilute the most valuable information.

A number of witnesses told us that the focus should be on unexpected adverse reactions. Is the frequency of an adverse reaction important? These are questions we are still asking ourselves in committee. We believe that this issue has not yet been resolved. That is why we are going to question the government about this in committee.

For example, one witness, Bruce Carleton, a senior clinician scientist from the University of British Columbia and B.C. Children's Hospital, suggests looking at human genetics and drug biotransformation. According to Dr. Carleton, drug reactions have a genetic basis. If further genetic research were conducted, it would be possible to predict and avoid adverse drug reactions.

This is an indication of the complexity of detecting adverse reactions. We would have liked to see a more innovative, proactive approach that goes beyond just adverse drug reaction reporting. As I said, this is known as pharmacogenomics.

One of the major concerns we had in committee about the creation of a register of adverse effects and adverse reaction reporting by hospitals pertains to the method of post-market monitoring. As I said earlier, the effectiveness of post-market monitoring will depend on how the register of adverse drug effects is structured and on the effectiveness of feedback from health professionals, including pharmacists and physicians.

It is not enough to simply create registers and collect data. In her testimony on April 10, the Auditor General said that there were weaknesses in the analysis and interpretation of adverse events, and there was no proactive system to identify patterns that could signal a serious safety concern.

The committee's work could have enlightened the minister about this bill. As I was saying earlier, we would have liked for him to wait for our reactions and our recommendations after our three-month-long analysis on pharmacovigilance. Some witnesses also suggested that an independent evaluation board be created.

What about that? Will the bill cover that? We know that clinical trials are done by the manufacturers, and that often, a number of adverse effects are known, but are not revealed and the drug is put on the market. We would have liked to see an independent evaluation board, and a number of witnesses agreed.

The life cycle of a drug will supposedly be extended, but we would like this to be done not only by manufacturers, but also by an independent evaluation board throughout the life cycle of the drug. We know that drugs are often tested on certain patients, but other groups of people have not been tested—for example children and seniors—and often, these drugs have serious adverse effects if they are used.

The creation of a research centre of excellence, in partnership with our universities, has also been suggested. This centre could engage in pharmacoepidemiology studies that would be required by law and funded by the industry, but not conducted by the industry, which is currently the case. Another guide was suggested, one that would be much more proactive and independent in relation to the pharmaceutical industry.

Any mandatory adverse reaction report will be ineffective if not dealt with properly. That is more or less the conclusion reached by several witnesses who want the government to do something about this. Will Bill C-51 address all those concerns?

For now, as I said earlier, some drugs have been taken off the market, but they could have been not put on the market right away in the first place. The industry could have waited for further clinical trials to be done.

There are also fears that there is an attempt to shorten the process before a drug is put on the market. There are some fears about the life cycle of the drug and following it after it goes on the market. That is a step in the right direction, but there is also a fear that this would shorten the period before the certification of clinical trials. We heard this from several witnesses. Thus, the life cycle of a drug should not be an excuse for premarketing studies to be reduced nor for the door to be opened to such a possibility.

A number of witnesses have told us that they would like the minister to be open to certain amendments they would like to see made to this bill. It is hoped that the minister and this government will be open to the decision made during clause by clause consideration of the bill.

As I was saying earlier, the regulations are not yet available. Will they be satisfactory? It is hard to say. It is rather a blank cheque right now. We know that the regulation will give life to the bill.

The vote here in Parliament will send the bill to committee, as I think all hon. members want to address it. Work will be done in committee.

Nonetheless, we hope—I am saying this again because I do not want anyone to forget it—that the minister will be open to the various voices that have been heard. For three months, we have been studying the drug monitoring program and the new life cycle for drugs, which takes a different approach, namely that trials continue after the drug is put on the market, in the interest of human safety.

For example, we know that some people have died after taking certain drugs. We also know that often, for genetic reasons, some drugs should not be given to certain patients. There needs to be openness in order to better address this whole issue. We have to take into account all the problems we have in properly understanding the effects of drugs on patients, those who use these drugs.

Labelling was also discussed. Warnings have to be issued, for example, if a person is sick and there is a contraindication to taking a certain drug. We would hope that the minister is open to that and that this will address the entire problem.

We are in the process of reviewing this approach. Given the openness of the parliamentary secretary, who sits on our committee, he can relay the questions to the minister. We are counting on his openness in this matter and we hope he will be proactive and sympathetic to our demands.

[Wayne Easter, Liberal, Malpeque, PE]

Mr. Speaker, I am pleased to speak to Bill C-51. In fact, as my colleague from West Nova said earlier in his remarks, these are two bills in a row, Bill C-51 and Bill C-52, that we are certainly most interested in moving forward to committee for further technical analysis and more research, but we do believe the bills in principle need to be carried forward.

The section of the bill with which I really want to deal is on the food side of it. I think there is strong interest in ensuring that products are indeed safe. I would say there is an almost public wave for stronger action in this regard. There has been the recent incidence of unsafe food. Health and consumer products have underscored the need to modernize the Food and Drugs Act. The fact of the matter is that the act was developed in 1953 and these amendments certainly update the bill.

Basically, the bill would amend the Food and Drugs Act and modernize the regulatory system for foods and therapeutic products. It would improve the surveillance of benefits and risks of therapeutic products through their life cycle. It is designed to increase compliance and enforcement measures by corporations to encourage them to report adverse reactions or potential health threats associated with market products. It would, I will admit, give substantial regulatory power to the minister.

I know there are some concerns about that. We have a number of letters already. That is why it is so important for the bill to go to committee relatively quickly, so that the witness lists can be prepared and those concerns can be addressed. We certainly support the idea of improving the safety and health of Canadians. We are committed to improving the safety and health of Canadians. We support measures to strengthen the regulatory system to ensure that Canadians are able to access the safest and most effective food in the world as well as with therapeutic products.

I want to turn mainly to the food area of the bill and that is in clauses 4 through to 6. The bill would create new offences relating to food, therapeutic products and cosmetics. It would require licensing for importing food and for the interprovincial trade in food.

In a previous Parliament there was Bill C-27. We in fact looked fairly extensively at the regulations surrounding the importing of food and the interprovincial trade in food. In all seriousness, there had to be improvements made in that area to ensure that imported food was safe and met the same kind of regulatory requirements as indeed Canadian food had to meet.

This bill in all areas would expand the regulatory authority, but in the food area it would expand the power of inspectors. I want to point out that it is not our intent nor do I believe it is the government's intent or even the bureaucracy's intent that the expansion of the powers of inspectors is to be overbearing. It is to ensure that the human resources and the authority are there to deal with some of the incidences that can happen on grocery store shelves or that imported food can face.

I would put a caveat in. Those of us who are on the agriculture committee know that certainly more human resources must be added to the Canadian Food Inspection Agency for it to do its job. The government did indicate the other day that there are some budgetary measures in that regard, but there do need to be the human and financial resources for the Canadian Food Inspection Agency to do its job and the additional authorities granted to it through this bill.

I also want to underline the fact that one of the concerns that we raised at our committee level was that these costs should not be passed on to primary producers. We have had enough of that. Primary producers should not be the ones bearing the costs for food inspections in this country. That is a public safety and health and safety issue. It is a public responsibility and we would hope that the government takes that seriously and funds the Canadian Food Inspection Agency appropriately to do its job.

The new prohibited activity in the bill really gives the government the authority to take action if someone knowingly provides the minister with false or misleading information relating to any matter in this bill, whether someone knowingly is tampering with a food, therapeutic product or a cosmetic, including tampering with a label or package.

A number of years ago, we heard about a substantial number of those where people, as a hoax or a threat or an act of terrorism really, had sent out the word over the media or email, or by other means, that they had in fact tampered with a food product on a grocery store shelf. That creates tremendous concern among the consuming public. It certainly creates difficulties for the businesses so affected. Under this bill, I do believe there is more authority for the authorities themselves to deal with those matters where there are hoaxes or threats, or indeed actual tampering with food itself.

The other area in clause 4 will also prohibit the importing of food that is injurious to human health. That is an important aspect of the bill that was not there previously in terms of the trade that goes on. It is very important that imported food be treated in the same way as domestic food on the grocery store shelves, and that action be taken against companies or individuals who may have both exported into this country or the company that imported the food that is injurious to human health. That is a very important measure.

We tend, in this country, to take our food system for granted. Canadian farmers provide the safest food in the world. The problem is they are certainly not paid well enough for it. Canadians only pay 13.5% of their income and by early February, their food bills are paid for the year. We do not want anything to happen on those grocery store shelves that will reflect badly on the Canadian primary producers.

The last point that I would make, as I see I am running out of time, is a point I made the other day, but I will make it again. Canadian farmers do face a double standard from their own government regulations. We must be on a level playing field with the rest of the world. We cannot add another regulatory burden.

[Robert Thibault, Liberal, West Nova, NS]

Mr. Speaker, I thank all members of the House.

I do not want to shock the minister while he is still present in the House, but it will come as very difficult news to him that for two days in a row we have to find some level of agreement with the bill that he proposes to the House of Commons. I am looking forward to this bill being at committee and to having the opportunity to further explore it.

I am pleased with the answer he gave to the member for Mississauga South. It is consistent with the discussion I had with the parliamentary secretary as to the fears out there about natural health products and natural therapeutic products not being targeted by this bill. I think that fear was out there, so I think this will be necessary. As I understand it, we can be assured of the government's cooperation if modifications have to be made in the definitions or in the bill so that this can be clearly drawn out.

That leaves one area of concern that I have been receiving as critic and which members undoubtedly will hear about. It is the question of direct to consumer advertising. While I understand from the bureaucrats or the minister's officials that there is no intention in this bill to permit direct to consumer advertising, it does somewhat change the way it is dealt with.

In the past it was directly in the bill. The bill said that the only advertising on prescription products would be the name, quantity and price. They were the only things that could be advertised. In this case, my understanding of it is that this gives the governor in council the potential to write regulations concerning advertising.

My understanding is that it is not the intent to open up the advertising, but it does take it out of the hands of Parliament and of the committee. That would cause some concern, so I hope that the government, at committee level, will be willing to look at some modifications to the bill, some amendments that might clarify this.

It could be done in one of two ways. One is that we could do the process that we have used in certain elements of the Health Act, which is to bring the regulations to committee for approval. We could limit it to those regulations concerning advertising, because it does not have to be all the regulations permitted under the act, or an amendment straight to the act. I will give some time for the government to consider those amendments before it comes to the committee. Hopefully, they will be negotiated amendments. If not, I am sure we will have some present.

That being said, I think the principles of this bill are quite good. This is not a bill that has been dreamt up in the last few weeks by the government. This bill is a result of a process of discussions and consultations that has been going on since 2003. These are part of the process that was known at the time as the smart regulations process. We were looking at regulatory reforms to the Government of Canada acts that necessitated those regulations to see if there was not a better way to do it, to be competitive internationally and domestically, and to at the same time protect Canadians.

One of the elements that comes in here is drug safety. The assurance of drug safety is very difficult. As the minister pointed out, the test on permitting or licensing of pharmaceutical products is whether the potential benefits outweigh the potential risks. We do not necessarily know when that first evaluation is done what the use of that pharmaceutical product will be in time, whether it will evolve from when the original clinical trials were done, and whether other drugs or therapies will come on stream that might interact with it. We do not know that.

Here we are going with the principle that has been known as progressive licensing and is now termed life cycle approvals or a life cycle approach. I do not know what it could be called that would reflect its true nature, but what it does is say that to get on the market initially the product has to meet the same safety criteria as it is currently meeting. The criteria are not relaxed.

Once the product is on the market, Health Canada has the ability to order further clinical trials or withdraw the licence if there is no compliance. I think that is important, because there could have been such a strict restrictive process, so as to assure absolute safety, that no new pharmaceuticals would ever come on the market.

However, with this process, we assure the safety of the product through clinical trials, and then we have time to do the evaluation as it is being used in the market, because the absolute use might be different from the use that had been foreseen. We heard at committee that the United States food and drug regulations use the 10,000 dosage system. After 10,000 dosages, they do a re-evaluation. Here, it could be different for any therapies.

However, once the experts at Health Canada see how a drug is evolving in its use, they can order further clinical trials at any time. I think it is important to try to understand what this means.

Number one, we know that almost no pharmaceuticals, and I could almost say zero, are approved for use by children. They are very seldom approved for use in pediatrics because it is so difficult to do clinical trials for pediatrics. The clinical trials before the first approval of a drug are done with adults. Then, over time, dosages or uses of prescriptions are studied by specialists in their work. When they find there is some value for use in pediatrics, they try to find the right dosage.

A drug might be developed for one specific use. For example, we have heard about Viagra being used in pediatric care, and while a drug might be developed for one specific use, it can be found through time that it is even more useful for other conditions that had not been considered. This is called off-label use.

I remember reading not so long ago about a cancer drug being used for macular degeneration. It was just as effective as the drug that had been used for macular degeneration. Thus, we can see how a drug might be used in a therapy other than the purpose for which it had its first clinical trials.

We now have the ability, with this bill, for Health Canada to order clinical trials in that area of use and in that population. If we discover with time that the major use of a certain therapy or pharmaceutical product ends up being done by seniors, those between the ages of 50 and 65, then perhaps Health Canada could order that a specific clinical trial be done in that area. If it is for people who have certain diseases and there are risks, we can do those things.

That is a logical, smart approach, which permits the drug to come on the market under the same criteria that it does now. This is what I think Canadians have to understand: this is not the relaxation of the initial criteria. It is a reasonable, intelligent way of monitoring the use of that product over time and changing the licensing standards.

Again, I think it is important to respond to the scare that is being put out there, because there are a lot of Canadians who are finding very good benefits in using non-prescription health products, therapeutic products, natural health products, organics, or whatever we want to call them. They are under different names. People are concerned when they see this bill that it might mean they can no longer access those products. I have had calls about this, as all the members of Parliament will.

I take the minister at his word. When I read the bill, I did not see any effect on the natural health product directorate and I did not see that these products were moved, but the fear is out there among Canadians and I think we will have to ensure, before the bill goes through the House of Commons and the Senate, that it is cleared up.

Yesterday when we were looking at Bill C-52, I raised a question on the power to recall and said that we have to be careful. We have to be careful that the power to recall does not become an obligation to recall. If we give the power to the minister and his inspectors, we have to make sure that this power is used only when all other methods fail and only when all other methods have been attempted, because we do not know of any problems we have had so far. So far, negotiations have been successful.

I see that my time has run out. I thank members for their attention.

[Christiane Gagnon, Bloc, Québec, QC]

Mr. Speaker, I have a few questions for the minister about Bills C-51 and C-52. We know that the bill will require more human resources and also a training budget. We are all anxious to see how the minister will meet expectations in implementing his bill.

In 2006, the Auditor General noted the lack of human resources, especially in the areas of training and the safety of therapeutic products, foods and cosmetics. There is a shortage of resources.

The minister mentioned natural products. He is certainly aware that there are delays in granting authorizations to sell natural products. That is my first question.

As for my second question, the minister knows that these two bills rely on regulations. Since the regulations do not yet exist, we will have a bill but will not know what sort of regulations will be made. These regulations could give us an idea of how the bill will be interpreted. Can the minister tell me when the regulations will be ready—